前列腺初次磁共振/超声融合引导靶向穿刺活检的表现
本研究纳入318例未活检且mpMRI PI-RADS≥3的男性,行经直肠靶向穿刺(TB)联合10针系统穿刺(SB)。总体癌症检出率77%,TB单独67%、SB单独70%;联合TB/SB在PI-RADS 3/4/5的检出率分别为38%、78%、95%。联合TB/SB诊断临床显著前列腺癌195例(61%),TB单独163例(51%);TB单独漏诊或低估Gleason≥8者31例(10%,P<0.001),SB单独21例(7%,P<0.001)。联合与TB单独的无意义前列腺癌比例均为16%。
要点
- 联合TB/SB的总体癌症检出率为77%,TB单独67%、SB单独70%。
- PI-RADS 3/4/5联合TB/SB的癌症检出率分别为38%、78%、95%。
- 联合TB/SB诊断临床显著前列腺癌195例(61%),TB单独163例(51%)。
核心结论
- 活检前mpMRI对未活检且怀疑前列腺癌的患者提高临床显著前列腺癌检出有增量价值。
- 联合TB与SB进一步提高诊断准确性且不增加无意义前列腺癌比例。
研究设计与样本
- 分析2012年1月至2016年12月318例连续未活检、mpMRI PI-RADS≥3的男性,行经直肠TB联合10针SB。
- TB采用基于传感器的MRI/US融合引导平台;mpMRI指征由治疗泌尿科医生根据临床参数在入院前决定。
主要发现
- 每例中位穿刺针数14(IQR 13-14);总体癌症检出率77%(245/318)。
- TB单独检出67%前列腺癌,SB单独检出70%。
- 联合TB/SB在PI-RADS 3/4/5的癌症检出率分别为38%(21/55)、78%(120/154)、95%(104/109)。
- 联合TB/SB诊断临床显著前列腺癌195例(61%),TB单独163例(51%)。
- 与联合TB/SB相比,TB单独漏诊或低估Gleason≥8者31例(10%,P<0.001),SB单独21例(7%,P<0.001)。
关键数值与推荐
- 临床显著前列腺癌定义为Gleason评分≥4+3=7(ISUP分级3)或最大癌芯长度≥6 mm。
- mpMRI可疑定义为PI-RADS评分≥3。
临床怎么用
- 对未活检且mpMRI PI-RADS≥3的怀疑前列腺癌患者,可考虑活检前mpMRI并联合TB与SB以提高临床显著前列腺癌检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the performance of a primary magnetic resonance imaging (MRI)/ultrasonography (US) fusion-guided targeted biopsy (TB), and in combination with an added systematic biopsy (SB). PATIENTS AND METHODS: Analysis of 318 consecutive biopsy-naïve men with suspicious multiparametric MRI (mpMRI; Prostate Imaging Reporting and Data System [PI-RADS] score ≥3) undergoing transrectal TB and 10-core SB between January 2012 and December 2016. The indication for performing mpMRI was based on clinical parameters and decided by the treating urologist before admission. TB was performed with a sensor-based MRI/US fusion-guided platform. Clinically significant prostate cancer was defined as Gleason score ≥4 + 3 = 7 (International Society of Urological Pathology Grade [ISUP] grade 3) or maximum cancer core length of ≥6 mm. RESULTS: A median (interquartile range) of 14 (13-14) biopsies per case were taken. The overall cancer detection rate (CDR) was 77% (245/318). The TB alone detected 67% of prostate cancers and the SB alone detected 70%. The PI-RADS dependent CDR for the combination of TB/SB were 38% (21/55), 78% (120/154) and 95% (104/109) for PI-RADS scores of 3/4/5, respectively. Clinically significant prostate cancer was diagnosed by the combination of TB and SB in 195 men (61%) and by TB alone in 163 cases (51%). The number of missed or underestimated prostate cancers with a Gleason score ≥8 for TB alone was 31 (10%, P < 0.001) and 21 (7%, P < 0.001) for SB alone in comparison with the results of the combination of TB and SB. The rate of insignificant prostate cancer was comparable for the combination of TB and SB and TB alone (50/318, 16% vs 50/318, 16%). CONCLUSIONS: Pre-biopsy mpMRI is of incremental value in increasing the detection of clinically significant prostate cancer in biopsy-naïve patients with suspicion of prostate cancer. Combining TB with SB further improved the diagnostic accuracy without increasing the rate of insignificant prostate cancer.
引用
- Maxeiner A, Kittner B, Blobel C, et al. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate. BJU Int. 2018. PMID: 29569320. doi:10.1111/bju.14212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。